Skip to main
IRD
IRD logo

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc. is advancing its pipeline of innovative gene therapies for inherited retinal diseases, showcasing promising efficacy results, notably a substantial increase in object recognition by treated patients and significant patient-reported improvements in near vision. The recent updates from the European Medicines Agency (EMA) and positive clinical data suggest a favorable trajectory for Opus's regulatory pathway and underscore the potential for accelerated approvals. Additionally, the data indicating robust visual acuity improvements and a significant response rate in treated patients compared to placebo strengthen the outlook on the company's ability to meet unmet medical needs in the ophthalmic field, potentially leading to strong market demand for its therapies.

Bears say

Opus Genetics Inc has consistently reported significant losses since its inception, raising concerns about the sustainability of its business model. Although R&D expenses decreased from $9.0 million to $6.4 million year-over-year, ongoing financial strain remains evident, pointing to challenges in managing operational costs. Furthermore, the presence of increasing market competition from emerging therapies targeting similar inherited retinal diseases poses a substantial risk to Opus's potential market share and pricing strategies, further contributing to a negative outlook for the company's stock.

Opus Genetics (IRD) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.